Thomas John Charles 4

What Happened

Thomas John Charles, EVP and General Counsel of Krystal Biotech (KRYS), exercised 1,000 options and sold 1,000 shares on June 25, 2026. He exercised options at $179.25 per share (cost $179,250) and sold 1,000 shares in an open-market transaction at $347.27 per share, generating proceeds of $347,270. The filing also reports a related derivative conversion/disposition at $0 (the option instrument was converted/terminated).

Key Details

• Transaction date: 2026-06-25
  • Exercise (M): 1,000 shares acquired at $179.25 each — total $179,250
  • Sale (S): 1,000 shares sold at $347.27 each — proceeds $347,270
  • Conversion/Disposition (M): 1,000 derivative units reported disposed at $0 (reflects option conversion/termination)
• Shares owned after the transactions: not disclosed in the provided excerpt of the filing
• Footnotes:
  • F1: All transactions were effected under a Rule 10b5-1 trading plan adopted Feb 23, 2026; the plan’s contemplated transactions are complete and the plan has terminated.
  • F2: The options vest ratably over a four‑year period beginning Feb 28, 2026.
• No late filing was indicated in the provided information.

Context

Because the acquired shares from the option exercise were sold the same day, this effectively functioned like a cashless exercise (exercise followed by immediate sale). The activity was executed under a pre-arranged 10b5-1 plan, which is commonly used to automate insider trades and reduce questions about timing or intent. As always, sales by insiders can be routine (tax or liquidity needs) and do not by themselves indicate a change in company outlook.